Online citations, reference lists, and bibliographies.
← Back to Search

Adamantinomatous And Papillary Craniopharyngiomas Are Characterized By Distinct Epigenomic As Well As Mutational And Transcriptomic Profiles

A. Hoelsken, M. Sill, J. Merkle, L. Schweizer, M. Buchfelder, J. Flitsch, R. Fahlbusch, M. Metzler, M. Kool, S. Pfister, A. von Deimling, D. Capper, D. Jones, R. Buslei
Published 2016 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction Craniopharyngiomas (CP) are rare epithelial tumors of the sellar region. Two subtypes, adamantinomatous (adaCP) and papillary CP (papCP), were previously identified based on histomorphological and epidemiological aspects. Recent data indicates that both variants are defined by specific genetic alterations, and influenced by distinct molecular pathways and particular origins. The fact that CP is an uncommon tumor entity renders studies on large cohorts difficult and exceptional. In order to achieve further insights distinguishing CP variants, we conducted whole genome methylation (450 k array) and microarray-based gene expression studies in addition to CTNNB1 and BRAF mutation analysis using a comprehensive cohort of 80 adaCP and 35 papCP.ResultsBRAFV600E mutations were solely found in the papCP subgroup and were not detectable in adaCP samples. In contrast, CTNNB1 mutations were exclusively detected in adaCP. The methylome fingerprints assigned DNA specimens to entity-specific groups (papCP (n = 18); adaCP (n = 25)) matching perfectly with histology-based diagnosis, suggesting that they represent truly distinct biological entities. However, we were not able to detect within the adaCP group (including 11 pediatric and 14 adult cases) a significant difference in methylation signature by age. Integrative comparison of the papCP with the adaCP group based on differential gene expression and methylation revealed a distinct upregulation of Wnt- and SHH signaling pathway genes in adaCP.ConclusionsAdaCP and papCP thus represent distinct tumor subtypes that harbor mutually exclusive gene mutations and methylation patterns, further reflected in differences in gene expression. This study demonstrates that DNA methylation analyses are an additional method to classify CP into subtypes, and implicates a role of epigenetic mechanisms in the genesis of the respective CP variants. Detection of tumor-specific signaling pathway activation enables the possibility of target-oriented intervention.
This paper references
10.1530/EJE-11-0158
Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up.
H. Müller (2011)
Handb Clin Neurol
Hl Muller (2014)
10.1097/00006123-199412000-00001
Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome.
H. Weiner (1994)
10.1007/s00428-009-0873-0
A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas
S. Burghaus (2009)
10.32388/apxnrh
Craniopharyngioma.
M. Garnett (2007)
10.1186/s40478-015-0211-5
Identification of targets for rational pharmacological therapy in childhood craniopharyngioma
J. Gump (2015)
10.1073/pnas.1101553108
Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans
C. Gaston-Massuet (2011)
10.1111/bpa.12148
Insights into the Infiltrative Behavior of Adamantinomatous Craniopharyngioma in a New Xenotransplant Mouse Model
C. Stache (2015)
10.1007/s11060-015-1757-6
BRAF V600E mutation is a useful marker for differentiating Rathke’s cleft cyst with squamous metaplasia from papillary craniopharyngioma
J. Kim (2015)
10.1056/NEJMoa1002011
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
10.1007/s00401-011-0802-6
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
G. Schindler (2011)
10.1002/path.1562
Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma
K. Kato (2004)
10.1093/neuonc/not195
Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth.
C. Stache (2014)
Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.
S. Sekine (2002)
10.1007/s00401-012-0957-9
Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma
C. Andoniadou (2012)
10.1371/journal.pone.0007887
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
L. Macconaill (2009)
The classification of tumours of the central nervous system.
R. O. Barnard (1982)
10.1371/journal.pone.0017948
BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
D. Dias-Santagata (2011)
10.1007/s00401-007-0243-4
The 2007 WHO Classification of Tumours of the Central Nervous System
D. N. Louis (2007)
10.1093/neuonc/nou223
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Q. Ostrom (2014)
10.1016/B978-0-444-59602-4.00016-2
Chapter 16 - Craniopharyngioma
H. Müller (2014)
Consensus Clustering: A ResamplingBased Method for Class Discovery and Visualization of Gene Expression Microarray Data
S Monti (2003)
10.1007/s00401-006-0184-3
Nuclear β-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas
R. Buslei (2006)
10.1007/s00401-010-0642-9
Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling
A. Hoelsken (2010)
10.1016/S0002-9440(10)64477-X
Short Communication Craniopharyngiomas of Adamantinomatous Type Harbor -Catenin Gene Mutations
S. Sekine (2002)
Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE.
B. Budowle (1991)
10.1007/s00401-014-1270-6
BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma
Sarah J. Larkin (2014)
10.3171/jns.1998.89.4.0547
The descriptive epidemiology of craniopharyngioma.
G. Bunin (1997)
10.1515/jpem-2014-0442
Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models
J. P. Martinez-Barbera (2015)
10.1111/nan.12201
BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts
L. Schweizer (2015)
10.1016/j.wneu.2012.07.033
Predictive factors for craniopharyngioma recurrence: a systematic review and illustrative case report of a rapid recurrence.
R. Prieto (2013)
Endocrinol Metab Clin North Am
N Karavitaki (2008)
10.1111/j.1750-3639.2008.00180.x
Target Gene Activation of the Wnt Signaling Pathway in Nuclear β‐Catenin Accumulating Cells of Adamantinomatous Craniopharyngiomas
A. Hoelsken (2009)
10.1093/jnci/djv310
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
P. Brastianos (2016)
10.1111/j.1440-1789.2011.01235.x
Coexistence of adamantinomatous and squamous‐papillary type craniopharyngioma: Case report and discussion of etiology and pathology
Tomu Okada (2012)
10.3171/JNS.1995.83.2.0206
Papillary craniopharyngioma: a clinicopathological study of 48 cases.
T. Crotty (1995)
10.1007/s00401-005-1004-x
Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region
R. Buslei (2005)
10.1016/j.stem.2013.07.004
Sox2(+) stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential.
C. Andoniadou (2013)
10.1007/s00401-011-0841-z
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
D. Capper (2011)
10.1007/s00381-005-1181-x
Epidemiology of pediatric tumors of the nervous system according to the WHO 2000 classification: a report of 1,195 cases from a single institution
S. Rosemberg (2005)
10.1586/ern.10.15
Childhood craniopharyngioma: current controversies on management in diagnostics, treatment and follow-up
H. Müller (2010)
10.1097/01.pas.0000213328.64121.12
Nuclear β-Catenin Accumulation as Reliable Marker for the Differentiation Between Cystic Craniopharyngiomas and Rathke Cleft Cysts: A Clinico-Pathologic Approach
B. Hofmann (2006)
10.1007/s11060-011-0540-6
Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults
E. H. Nielsen (2011)
10.1158/1078-0432.CCR-10-2811
EGFR Signaling Regulates Tumor Cell Migration in Craniopharyngiomas
A. Hoelsken (2011)
10.1007/s003810050231
Epidemiology and prognosis in children treated for intracranial tumours in Denmark 1960–1984
F. Gjerris (1998)
10.1007/s11102-015-0663-4
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
S. Aylwin (2015)
10.1007/s11102-013-0543-8
Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche?
A. Hoelsken (2013)
10.1093/neuonc/nos218
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.
T. A. Dolecek (2012)
10.1111/j.1365-2559.2004.02029.x
Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma: evidence for its odontogenic epithelial differentiation
S. Sekine (2004)
10.1023/A:1023949509487
Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data
S. Monti (2004)
10.1056/NEJMc1202124
BRAF inhibition in refractory hairy-cell leukemia.
S. Dietrich (2012)
Craniopharyngiomas. Endocr Rev
N Karavitaki (2006)
10.1210/jc.2011-2187
Craniopharyngiomas express embryonic stem cell markers (SOX2, OCT4, KLF4, and SOX9) as pituitary stem cells but do not coexpress RET/GFRA3 receptors.
M. García-Lavandeira (2012)
10.1038/ng.2868
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
P. Brastianos (2014)



This paper is referenced by
10.1038/s41417-018-0015-4
Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma
J. Yang (2018)
10.1093/jnen/nlw116
Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma
T. Goschzik (2017)
10.1111/bpa.12525
Preclinical transgenic and patient‐derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma
Jessica K. R. Boult (2018)
University of Birmingham The medical therapy of craniopharyngiomas
K. Alexandraki (2019)
10.21037/24882
Value of magnetic resonance imaging in predicting BRAF mutation in craniopharyngiomas
M. Giordano (2019)
10.1007/978-3-319-51890-9_3
Genetically modified mouse models of adamantinomatous craniopharyngioma
C. Andoniadou (2017)
10.18632/oncotarget.10501
TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology
Y. Liu (2016)
10.2147/IMCRJ.S243405
Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis
R. Jastania (2020)
10.1016/j.oooo.2018.11.004
Craniopharyngiomas and odontogenic tumors mimic normal odontogenesis and share genetic mutations, histopathologic features, and molecular pathways activation.
C. Gomes (2019)
10.1007/978-3-030-41176-3
Adult Craniopharyngiomas: Differences and Lessons from Paediatrics
Emmanuel Jouanneau (2020)
10.1371/journal.pone.0197895
Characterization of the murine orthotopic adamantinomatous craniopharyngioma PDX model by MRI in correlation with histology
A. Hoelsken (2018)
10.3390/jcm9020519
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
Ros Whelan (2020)
10.3390/cancers11070890
Leveraging the Role of the Metastatic Associated Protein Anterior Gradient Homologue 2 in Unfolded Protein Degradation: A Novel Therapeutic Biomarker for Cancer
Reem Alsereihi (2019)
10.1093/neuonc/noy035
Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma
S. Coy (2018)
10.3171/2018.3.FOCUS1861
Craniopharyngioma: a roadmap for scientific translation.
Saksham Gupta (2018)
10.1016/j.wneu.2019.06.037
Is gross total resection reasonable in adults with craniopharyngiomas with hypothalamic involvement ?
C. Apra (2019)
10.1002/pbc.26861
Adolescents and young adults with brain tumors in the context of molecular advances in neuro‐oncology
M. Zapotocky (2018)
10.1155/2019/3609789
Investigating the Protein Signature of Adamantinomatous Craniopharyngioma Pediatric Brain Tumor Tissue: Towards the Comprehension of Its Aggressive Behavior
C. Martelli (2019)
10.3171/2016.9.FOCUS16308
Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Leslie C. Robinson (2016)
10.1038/s41598-017-15977-3
Expression of SRY-related HMG Box Transcription Factors (Sox) 2 and 9 in Craniopharyngioma Subtypes and Surrounding Brain Tissue
V. Thimsen (2017)
10.1159/000506904
Biological Behaviour of Craniopharyngiomas
J. P. Martinez-Barbera (2020)
Recent advances in molecular pathology of craniopharyngioma [version 1; peer review: 2 approved]
Karavitaki (2019)
10.1007/s10689-019-00126-8
Pediatric craniopharyngioma in association with familial adenomatous polyposis
N. Dahl (2019)
10.1007/978-3-319-51890-9_2
Transcriptomic and Genomic Analyses of Human Craniopharyngioma
Leslie E Robinson (2017)
10.1038/nrneurol.2016.173
Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification
I. Blümcke (2016)
10.1007/978-3-030-11339-1_3
Adamantinomatous Craniopharyngioma: Genomics, Radiologic Findings, Clinical, and Prognosis
H. Müller (2019)
10.1530/JOE-17-0258
Stem/progenitor cells in pituitary organ homeostasis and tumourigenesis
S. Haston (2018)
10.1186/s12883-018-1216-z
Noninvasive molecular diagnosis of craniopharyngioma with MRI-based radiomics approach
X. Chen (2019)
10.3171/2016.9.FOCUS16316
Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
C. Stache (2016)
10.3389/fgene.2018.00049
Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma
Sven-Martin Schlaffer (2018)
10.1038/modpathol.2016.153
Distinct patterns of primary and motile cilia in Rathke’s cleft cysts and craniopharyngioma subtypes
S. Coy (2016)
10.1007/s00401-017-1678-x
Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma
Adriana Olar (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar